DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Chevy Chase Trust Holdings Inc.

Chevy Chase Trust Holdings Inc. boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 10.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,889 shares of the medical device company’s stock after buying an additional 4,399 shares during the period. Chevy Chase Trust Holdings Inc. owned approximately 0.05% of DexCom worth $3,430,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in DXCM. Bank of Montreal Can raised its stake in DexCom by 69.2% in the second quarter. Bank of Montreal Can now owns 31,403 shares of the medical device company’s stock valued at $2,296,000 after buying an additional 12,847 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in DexCom during the second quarter valued at about $322,000. Xact Kapitalforvaltning AB raised its stake in DexCom by 2.3% in the second quarter. Xact Kapitalforvaltning AB now owns 10,954 shares of the medical device company’s stock valued at $801,000 after buying an additional 250 shares in the last quarter. Handelsbanken Fonder AB raised its stake in DexCom by 115.0% in the second quarter. Handelsbanken Fonder AB now owns 21,500 shares of the medical device company’s stock valued at $1,573,000 after buying an additional 11,500 shares in the last quarter. Finally, Independent Portfolio Consultants Inc. increased its position in DexCom by 0.4% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after buying an additional 9 shares during the last quarter.

DexCom, Inc. (NASDAQ DXCM) traded up 0.58% during mid-day trading on Friday, reaching $73.20. The company’s stock had a trading volume of 1,234,880 shares. DexCom, Inc. has a 12-month low of $57.68 and a 12-month high of $96.38. The stock’s market cap is $6.34 billion. The firm’s 50 day moving average price is $70.65 and its 200 day moving average price is $74.95.

DexCom (NASDAQ:DXCM) last issued its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. The firm had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The firm’s revenue for the quarter was up 24.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.24) earnings per share. On average, equities analysts predict that DexCom, Inc. will post ($0.77) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by BNB Daily and is owned by of BNB Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of international trademark and copyright laws. The correct version of this news story can be read at https://www.baseball-news-blog.com/2017/08/19/chevy-chase-trust-holdings-inc-increases-position-in-dexcom-inc-nasdaqdxcm-updated-updated-updated.html.

DXCM has been the subject of several recent analyst reports. B. Riley restated a “buy” rating and issued a $95.00 price target on shares of DexCom in a research note on Thursday, April 27th. William Blair restated an “outperform” rating on shares of DexCom in a research note on Thursday, April 27th. BTIG Research downgraded DexCom from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 3rd. Canaccord Genuity lowered their target price on DexCom from $95.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 3rd. Finally, Oppenheimer Holdings, Inc. set a $98.00 target price on DexCom and gave the company a “buy” rating in a research report on Wednesday, May 3rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company. DexCom presently has a consensus rating of “Buy” and an average price target of $87.00.

In other DexCom news, EVP Andrew K. Balo sold 3,244 shares of the business’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $71.18, for a total transaction of $230,907.92. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $69.07, for a total value of $414,420.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,726 shares of company stock worth $2,376,466. 1.70% of the stock is currently owned by insiders.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply